Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $2.1 million.

  • Gain Therapeutics' Net Cash Flow rose 13998.82% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 14270.15%. This contributed to the annual value of -$884244.0 for FY2024, which is 12211.64% down from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Net Cash Flow is $2.1 million, which was up 13998.82% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Net Cash Flow registered a high of $39.2 million during Q1 2021, and its lowest value of -$19.9 million during Q2 2022.
  • Its 5-year average for Net Cash Flow is $48668.4, with a median of -$1.9 million in 2023.
  • Over the last 5 years, Gain Therapeutics' Net Cash Flow had its largest YoY gain of 606582.99% in 2021, and its largest YoY loss of 69441.96% in 2021.
  • Over the past 5 years, Gain Therapeutics' Net Cash Flow (Quarter) stood at -$4.2 million in 2021, then rose by 8.99% to -$3.8 million in 2022, then surged by 285.69% to $7.0 million in 2023, then plummeted by 116.83% to -$1.2 million in 2024, then surged by 277.72% to $2.1 million in 2025.
  • Its Net Cash Flow stands at $2.1 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$1.4 million for Q1 2025.